Concepedia
Statistics
Publications
38
Citations
4K
H-Index
27
Active since
2007
Affiliations
Dana-Farber Cancer Institute(Current)
Harvard University
Massachusetts General Hospital
Brigham and Women's Hospital
VA Boston Healthcare System
Diana Cirstea is an author at Dana-Farber Cancer Institute specializing in multiple myeloma, medicine, and multiple myeloma therapy.
Publications per year
2007–2025
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
Loredana Santo, Teru Hideshima, Andrew L. Kung et al. · Blood · 2012 · 601 citations · Full text
Medicine, Pharmacokinetics, Pharmacology +15
Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma
Naoya Mimura, Mariateresa Fulciniti, Güllü Görgün et al. · Blood · 2012 · 435 citations · Full text
Life Sciences, Molecular Biology, Molecular Medicine +9
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma
Güllü Görgün, Elisabetta Calabrese, Teru Hideshima et al. · Blood · 2010 · 275 citations
Medicine, Cancer Biology, Oncology +16
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease
Sonia Vallet, Siddhartha Mukherjee, Nileshwari Vaghela et al. · Proceedings of the National Academy of Sciences · 2010 · 235 citations · Full text
Medicine, Cell Biology, Oncology +17
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma
Güllü Görgün, Elisabetta Calabrese, Ender Soydan et al. · Blood · 2010 · 231 citations · Full text
Medicine, Hematology, Immunology +16
1–5 of 38